No takes yet. Share an insight, caveat, or question.
Phase I trial reveals AQP3 as a key target to reduce lethal pulmonary toxicity in ovarian cancer treatments, suggesting safer CAR-T cell therapy options.
Xiang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: